Boehringer Ingelheim and Cue Biopharma Inc., a clinical-stage biopharmaceutical company, have joined forces to develop and commercialize Cue Biopharma’s CUE-501 product candidate, a differentiated B cell depletion therapy for autoimmune diseases. Cue Biopharma’s preclinical candidate molecule binds to a B cell specific membrane protein and, in parallel, selectively engages virus-specific memory killer T cells. This enables it to selectively deplete B cells and dampen autoimmune and inflammato...